Compare PXED & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | BHVN |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2025 | 2017 |
| Metric | PXED | BHVN |
|---|---|---|
| Price | $31.78 | $11.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $45.00 | $29.43 |
| AVG Volume (30 Days) | 142.8K | ★ 3.2M |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $1,007,192,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $4.86 | $1,147.70 |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $23.52 | $7.48 |
| 52 Week High | $47.08 | $44.28 |
| Indicator | PXED | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.08 |
| Support Level | N/A | $9.32 |
| Resistance Level | N/A | $11.72 |
| Average True Range (ATR) | 0.00 | 1.03 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 92.96 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.